Search

Your search keyword '"FITZGERALD, O."' showing total 1,349 results
Start Over Author "FITZGERALD, O."
1,349 results on '"FITZGERALD, O."'

1. OP0308 MULTI-OMICS APPROACH TO THE IDENTIFICATION OF BIOMARKERS FOR PROGRESSION FROM PSORIASIS TO PSORIATIC ARTHRITIS

Author

Pennington, S. R., primary, Schwenk, J., additional, Bendes, A., additional, Rischke, S., additional, Gurke, R., additional, Hahnefeld, L., additional, Kirby, B., additional, Coates, L. C., additional, Coleman, O., additional, Waddington, J., additional, Zhou, R., additional, Wundervald, B., additional, Whitfield, P., additional, Blackburn, G., additional, Regnault, C., additional, Barton, A., additional, Bowes, J., additional, Bluett, J., additional, and Fitzgerald, O., additional

Published
2024
Full Text
View/download PDF

2. OP0270 MICROSTRUCTURAL DAMAGE PROGRESSION OVER A 10-YEAR OBSERVATION PERIOD IN PATIENTS WITH PSORIATIC ARTHRITIS ASSESSED BY HIGH-RESOLUTION QUANTITATIVE PERIPHERAL COMPUTED TOMOGRAPHY: RESULTS FROM THE COMPACT STUDY

Author

Fagni, F., primary, Tascilar, K., additional, Schuster, L., additional, Yalcin Mutlu, M., additional, Temiz, S. A., additional, Bayat, S., additional, Fitzgerald, O., additional, Pennington, S. R., additional, Martin, D., additional, Kleyer, A., additional, Simon, D., additional, and Schett, G., additional

Published
2024
Full Text
View/download PDF

7. Executive Retreat: proceedings of the GRAPPA Executive Retreat 2022

Author

Ng, B, Jadon, D, Adebajo, A, Ayan, G, Callis Duffin, K, Chandran, V, Coates, LC, D’Agostino, MA, de Vlam, K, Deodhar, A, Eder, L, Garg, A, Gladman, DD, Goel, N, Gottlieb, A, Husni, ME, Katz, A, Kavanaugh, A, Lubrano, E, Mease, P, Merola, J, Nash, P, Ogdie, A, Pennington, S, Perez-Chada, LM, Proft, F, Rosen, CF, Savage, L, Goldenstein-Schainberg, C, Siebert, S, Soriano, E, Steinkoenig, I, Tillett, W, Armstrong, A, and FitzGerald, O

Published
2023

10. Fees Must Fall: Student Revolt, Decolonisation And Governance In South Africa

Author

Susan Booysen, Gillian Godsell, Rekgotsofetse Chikane, Sizwe Mpofu-Walsh, Omhle Ntshingila, Refiloe Lepere, Swankie Mofoko, Ayabonga Nase, David Everatt, Lynn Hewlett, Nomagugu Masuku-Mukadah, Horácio Lucas Zandamela, Koffi Kouakou, William Gumede, Patrick Bond, Vishwas Satgar, Patrick Fitzgerald, O, Susan Booysen and Susan Booysen, Gillian Godsell, Rekgotsofetse Chikane, Sizwe Mpofu-Walsh, Omhle Ntshingila, Refiloe Lepere, Swankie Mofoko, Ayabonga Nase, David Everatt, Lynn Hewlett, Nomagugu Masuku-Mukadah, Horácio Lucas Zandamela, Koffi Kouakou, William Gumede, Patrick Bond, Vishwas Satgar, Patrick Fitzgerald, O, Susan Booysen

Published
2016

11. Comparative Genetic Analysis of Psoriatic Arthritis and Psoriasis for the Discovery of Genetic Risk Factors and Risk Prediction Modeling

Author

Soomro, M, Stadler, M, Dand, N, Bluett, J, Jadon, D, Jalali‐najafabadi, F, Duckworth, M, Ho, P, Marzo‐Ortega, H, Helliwell, PS, Ryan, AW, Kane, D, Korendowych, E, Simpson, MA, Packham, J, McManus, R, Gabay, C, Lamacchia, C, Nissen, MJ, Brown, MA, Verstappen, SMM, Van Staa, T, Barker, JN, Smith, CH, Chalmers, R, Flohr, C, Watson, K, Prieto‐Merino, D, Alabas, O, Barker, J, Becher, G, Bewley, A, Burden, D, Morrison, S, Laws, P, Evans, I, Griffiths, C, Ahmed, S, Kirby, B, Kleyn, E, Lawson, L, Mackenzie, T, McPherson, T, McElhone, K, Murphy, R, Ormerod, A, Owen, C, Reynolds, N, Rashid, A, Smith, C, Warren, R, Siebert, S, Brown, S, McAteer, H, Schofield, J, FitzGerald, O, McHugh, N, Warren, RB, Bowes, J, and Barton, A

Abstract

Objectives Psoriatic arthritis (PsA) has a strong genetic component, and the identification of genetic risk factors could help identify the ~30% of psoriasis patients at high risk of developing PsA. Our objectives were to identify genetic risk factors and pathways that differentiate PsA from cutaneous-only psoriasis (PsC) and to evaluate the performance of PsA risk prediction models. Methods Genome-wide meta-analyses were conducted separately for 5,065 patients with PsA and 21,286 healthy controls and separately for 4,340 patients with PsA and 6,431 patients with PsC. The heritability of PsA was calculated as a single-nucleotide polymorphism (SNP)–based heritability estimate (h2SNP) and biologic pathways that differentiate PsA from PsC were identified using Priority Index software. The generalizability of previously published PsA risk prediction pipelines was explored, and a risk prediction model was developed with external validation. Results We identified a novel genome-wide significant susceptibility locus for the development of PsA on chromosome 22q11 (rs5754467; P = 1.61 × 10−9), and key pathways that differentiate PsA from PsC, including NF-κB signaling (adjusted P = 1.4 × 10−45) and Wnt signaling (adjusted P = 9.5 × 10−58). The heritability of PsA in this cohort was found to be moderate (h2SNP = 0.63), which was similar to the heritability of PsC (h2SNP = 0.61). We observed modest performance of published classification pipelines (maximum area under the curve 0.61), with similar performance of a risk model derived using the current data. Conclusion Key biologic pathways associated with the development of PsA were identified, but the investigation of risk classification revealed modest utility in the available data sets, possibly because many of the PsC patients included in the present study were receiving treatments that are also effective in PsA. Future predictive models of PsA should be tested in PsC patients recruited from primary care.

Published
2022

12. Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase III studies

Author

Orbai, A-M, Mease, PJ, Helliwell, PS, FitzGerald, O, Fleishaker, DL, Mundayat, R, and Young, P

Subjects
Rheumatology
Abstract

Background Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA). This post-hoc analysis of two phase III studies in patients with PsA treated with tofacitinib assessed dactylitis by location, and the impact on patient-reported outcomes (PROs). Methods Patients received tofacitinib 5 or 10 mg twice daily (BID), or placebo. Endpoints included change from baseline in Dactylitis Severity Score (DSS), proportions of patients with dactylitis, Psoriatic Arthritis Disease Activity Score (PASDAS), and PROs (Health Assessment Questionnaire-Disability Index [HAQ-DI]; Functional Assessment of Chronic Illness Therapy-Fatigue [FACIT-F]; Short Form-36 Health Survey [SF-36] Physical Component Summary [PCS], Mental Component Summary [MCS], and physical functioning [PF]; arthritis pain; and Work Limitations Questionnaire [WLQ]). Descriptive statistics were generated by visit and treatment. Change from baseline in PROs were evaluated by multivariate linear regression. Results The analysis included 373/337 patients with baseline DSS > 0/DSS = 0. Regardless of location, DSS improvements in patients with DSS > 0 were greater from month 1 with tofacitinib (10 mg BID) versus placebo. For patients with DSS > 0/DSS = 0, both doses of tofacitinib led to mean dactylitis presence ≤ 15%/ Conclusion Tofacitinib resulted in sustained improvements in dactylitis irrespective of location, with minimal emergence of new dactylitis. Trial registration NCT01877668; NCT01882439.

Published
2022

13. POS1045 MASS SPECTROMETRY-BASED PROTEOMICS FOR THE IDENTIFICATION OF CANDIDATE SERUM PROTEIN BIOMARKERS THAT MAY PREDICT TREATMENT RESPONSE IN PATIENTS WITH PSORIATIC ARTHRITIS

Author

Waddington, J., primary, Zhou, R., additional, Coleman, O., additional, Wundervald, B., additional, Parnell, A., additional, Mease, P. J., additional, Chandran, V., additional, Fallon, L., additional, Chapman, D., additional, Pollock, R., additional, Deng, S., additional, Fitzgerald, O., additional, and Pennington, S., additional

Published
2022
Full Text
View/download PDF

14. POS0111 MORE METICULOUSLY FOLLOWING TREAT-TO-TARGET IN RA DOES NOT LEAD TO LESS RADIOGRAPHIC PROGRESSION: A LONGITUDINAL ANALYSIS IN BIODAM

Author

Ramiro, S., primary, Landewé, R. B. M., additional, Van der Heijde, D., additional, Sepriano, A., additional, Fitzgerald, O., additional, Østergaard, M., additional, Homik, J., additional, Elkayam, O., additional, Thorne, C., additional, Larché, M., additional, Ferraccioli, G., additional, Backhaus, M., additional, Boire, G., additional, Combe, B., additional, Schaeverbeke, T., additional, Saraux, A., additional, Dougados, M., additional, Rossini, M., additional, Govoni, M., additional, Sinigaglia, L., additional, Cantagrel, A., additional, Allaart, C., additional, Barnabe, C., additional, Bingham, C., additional, Van Schaardenburg, D., additional, Hammer, H. B., additional, Dadashova, R., additional, Hutchings, E., additional, Paschke, J., additional, and Maksymowych, W. P., additional

Published
2022
Full Text
View/download PDF

18. Epidemiology, genetics and management of psoriatic arthritis 2013: focus on developments of who develops the disease, its clinical features, and emerging treatment options

Author

Haroon M, FitzGerald O, and Winchester R

Subjects
Dermatology, RL1-803
Abstract

Muhammad Haroon,1 Oliver FitzGerald,1 Robert Winchester2 1Department of Rheumatology, St Vincent's University Hospital, Dublin, Ireland; 2Division of Rheumatology, Columbia University College of Physicians and Surgeons, New York, NY, USA Abstract: The picture of elements comprising the genetic susceptibility to develop psoriatic arthritis, especially those involving human leukocyte antigen alleles, is emerging in much greater clarity because of improvements in the methods of psoriatic arthritis ascertainment and in the technology of genetic typing. This new knowledge suggests there is genetic heterogeneity in the psoriasis phenotype, and that there are several genetically and clinically different forms of psoriatic arthritis. These genetic studies on psoriatic arthritis further reinforce the relationship of psoriatic arthritis to the other spondyloarthritides, but also raise novel questions of whether the effect of certain susceptibility genes may differ among them. Considerable evidence indicates that the clinical features reflect a CD8 T lymphocyte-driven immune response is present that is characterized by clonal expansion and differentiation towards memory-effector phenotypes. With the aid of new classification criteria, the typical clinical features of psoriatic arthritis involving different joints, entheses, and their related compartments are being better defined as distinctive characteristics of psoriatic arthritis or of the spondyloarthritis group of disorders. In the evaluation of an individual with psoriatic arthritis, taking a patient-focused perspective is recommended, which has the potential to enhance their quality of life significantly. The choice of current and emerging therapeutic agents from an increasing realm of conventional and biologic agents is becoming much better rationalized and more firmly based on evidence from clinical trials. Keywords: psoriatic arthritis, genetic susceptibility, heterogeneity, classification, diagnostic criteria, treatment

Published
2013

20. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update

Author

Gossec, L, Smolen, J S, Ramiro, S, de Wit, M, Cutolo, M, Dougados, M, Emery, P, Landewé, R, Oliver, S, Aletaha, D, Betteridge, N, Braun, J, Burmester, G, Cañete, J D, Damjanov, N, FitzGerald, O, Haglund, E, Helliwell, P, Kvien, T K, Lories, R, Luger, T, Maccarone, M, Marzo-Ortega, H, McGonagle, D, McInnes, I B, Olivieri, I, Pavelka, K, Schett, G, Sieper, J, van den Bosch, F, Veale, D J, Wollenhaupt, J, Zink, A, and van der Heijde, D

Published
2016
Full Text
View/download PDF

25. OP0229 THE GROUP FOR RESEARCH AND ASSESSMENT OF PSORIASIS AND PSORIATIC ARTHRITIS (GRAPPA) TREATMENT RECOMMENDATIONS 2021

Author

Coates, L. C., primary, Soriano, E., additional, Corp, N., additional, Bertheussen, H., additional, Callis-Duffin, K., additional, Barbosa Campanholo, C., additional, Chau, J., additional, Eder, L., additional, Fernandez, D., additional, Fitzgerald, O., additional, Garg, A., additional, Gladman, D. D., additional, Goel, N., additional, Grieb, S., additional, Helliwell, P., additional, Husni, M. E., additional, Jadon, D., additional, Katz, A., additional, Laheru, D., additional, Latella, J., additional, Leung, Y. Y., additional, Lindsay, C., additional, Lubrano, E., additional, Mazzuoccolo, L., additional, Mcdonald, R., additional, Mease, P. J., additional, O’sullivan, D., additional, Ogdie, A., additional, Olsder, W., additional, Schick, L., additional, Steinkoenig, I., additional, De Wit, M., additional, Van der Windt, D., additional, and Kavanaugh, A., additional

Published
2021
Full Text
View/download PDF

29. POS0043 PERIPHERAL QUANTITATIVE COMPUTED TOMOGRAPHY IN THE ASSESSMENT OF BONE MINERAL DENSITY IN ANTI-TNF-TREATED RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS PATIENTS

Author

Juhász, B., primary, Gulyás, K., additional, Horváth, Á., additional, Végh, E., additional, Pusztai, A., additional, Szentpetery, A., additional, Pethö, Z., additional, Bodnár, N., additional, Hamar, A., additional, Bodoki, L., additional, Bhattoa, H. P., additional, . Szekanecz, É, additional, Hodosi, K., additional, Domjan, A., additional, Szamosi, S., additional, Horváth, C., additional, Szántó, S., additional, Szücs, G., additional, Raterman, H., additional, Lems, W., additional, Fitzgerald, O., additional, and Szekanecz, Z., additional

Published
2021
Full Text
View/download PDF

30. AB0531 THERAPIES FOR PERIPHERAL JOINT INVOLVEMENT IN PSORIATIC ARTHRITIS: A SYSTEMATIC LITERATURE REVIEW

Author

Leung, Y. Y., primary, Korotaeva, T., additional, Candia, L., additional, Juhl Pedersen, S., additional, Bautista-Molano, W., additional, Ruderman, E., additional, Bisoendial, R., additional, Perez Alamino, R., additional, Olsder, W., additional, Moeller, B., additional, Grazio, S., additional, Gudu, T., additional, Mody, G., additional, Pineda, C., additional, Raffayova, H., additional, Rohekar, S., additional, and Fitzgerald, O., additional

Published
2021
Full Text
View/download PDF

32. Therapies for peripheral joint involvement in psoriatic arthritis: a systematic literaure review

Author

Leung, YY, Korotaeva, T, Candia, L, Juhi Pedersen, S, Bautista- MOlano, W, Ruderman, E, Bisoendial, R, Perez Alamino, R, Olsder, W, Moeller, B, Grazio, Simeon, Gudu, T, Mody, G, Pineda, C, Raffayova, H, Rohekar, S, and Fitzgerald, O

Subjects
psoriatic arthritis, treatment, systematic review
Abstract

Background: Much new information has been reported since the last evidence-based GRAPPA recommendations for the treatment of psoriasis and psoriatic arthritis (PsA). Objectives: We aimed to compile the evidence for the efficacy and safety of established and newly developed drugs targeting the peripheral arthritis domain in PsA so as to provide information for the revised GRAPPA treatment recommendations. Methods: A working group consisting of clinicians and patient research partners (PRPs) was convened. We performed an updated systematic literature review (SLR) of randomized controlled trials (RCTs) for the treatment of PsA, including peripheral arthritis, from the date of the last GRAPPA SLR, from February 19, 2013 to August 28, 2020. The working group reviewed the evidence supporting the efficacy on peripheral arthritis for each class of drug, according to the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach, for three patients groups: 1) naïve to treatment ; 2) refractory to conventional (-c)DMARDs ; and 3) with prior biological (-b)DMARD experience. We also evaluated the evidence for non-pharmacological treatments. A set of important outcomes for the peripheral arthritis domain was assessed for each class of medication. The certainty of evidence supporting each class of drugs for each patient group was evaluated. Recommendations were derived through consensus meetings. Results: 87 articles from 52 RCTs were included. For patients with mild disease who are naïve to treatment, the working group strongly recommends csDMARDs (methotrexate, sulfasalazine, leflunomide) and PDE4i, and weakly recommends them for severe disease, where TNFi are preferred over csDMARDs. Other bDMARDs (IL-17i, IL-12/23i, IL- 23i) and JAKi are strongly recommended to treat peripheral arthritis for treatment naïve patients. For patients with inadequate response to csDMARDs, we strongly recommend TNFi, IL-17i, IL-12/23i, IL- 23i and JAKi. For those who had prior experience with bDMARDs, we strongly recommend a second TNFi, IL-17i, IL-23i and JAKi. Certainty of evidence (GRADE) and recommendations for peripheral arthritis domain of PsA for different population groups are shown in Table 1. While the evidence supporting non-pharmacological treatments was low, we derived the recommendations from clinician/PRP expert opinion, included advocating an increase in physical activity, smoking cessation and a healthy diet to control weight gain. Conclusion: Evidence supporting drug treatment for the peripheral arthritis domain of PsA was compiled, providing required information for the revised GRAPPA treatment recommendations. Further work seeking agreement from a broader group of stakeholders is in progress.

Published
2021

33. Incorporating real-world evidence into the development of patient blood glucose prediction algorithms for the ICU

Author

Fitzgerald, O, Perez-Concha, O, Gallego, B, Saxena, MK, Rudd, L, Metke-Jimenez, A, Jorm, L, Fitzgerald, O, Perez-Concha, O, Gallego, B, Saxena, MK, Rudd, L, Metke-Jimenez, A, and Jorm, L

Abstract

Objective: Glycemic control is an important component of critical care. We present a data-driven method for predicting intensive care unit (ICU) patient response to glycemic control protocols while accounting for patient heterogeneity and variations in care. Materials and Methods: Using electronic medical records (EMRs) of 18 961 ICU admissions from the MIMIC-III dataset, including 318 574 blood glucose measurements, we train and validate a gradient boosted tree machine learning (ML) algorithm to forecast patient blood glucose and a 95% prediction interval at 2-hour intervals. The model uses as inputs irregular multivariate time series data relating to recent in-patient medical history and glycemic control, including previous blood glucose, nutrition, and insulin dosing. Results: Our forecasting model using routinely collected EMRs achieves performance comparable to previous models developed in planned research studies using continuous blood glucose monitoring. Model error, expressed as mean absolute percentage error is 16.5%-16.8%, with Clarke error grid analysis demonstrating that 97% of predictions would be clinically acceptable. The 95% prediction intervals achieve near intended coverage at 93%-94%. Discussion: ML algorithms built on observational data sources, such as EMRs, present a promising approach for personalization and automation of glycemic control in critical care. Future research may benefit from applying a combination of methodologies and data sources to develop robust methodologies that account for the variations seen in ICU patients and difficultly in detecting the extremes of observed blood glucose values. Conclusion: We demonstrate that EMRs can be used to train ML algorithms that may be suitable for incorporation into ICU decision support systems.

Published
2021

34. Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working Group.

Author

Leung Y.Y., Orbai A.-M., Tillett W., Ogdie A., Eder L., Goel N., Hojgaard P., Holland R., Mathew A.J., Lindsay C.A., Antony A., Chau J., Christensen R., Coates L.C., Mease P.J., Strand V., FitzGerald O., de Wit M., Duffin K.C., Gladman D.D., Leung Y.Y., Orbai A.-M., Tillett W., Ogdie A., Eder L., Goel N., Hojgaard P., Holland R., Mathew A.J., Lindsay C.A., Antony A., Chau J., Christensen R., Coates L.C., Mease P.J., Strand V., FitzGerald O., de Wit M., Duffin K.C., and Gladman D.D.

Abstract

The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Outcome Measures in Rheumatology (OMERACT) Psoriatic Arthritis (PsA) Working Group provided updates at the 2020 GRAPPA annual meeting on its work toward developing a core outcome set for PsA. Working groups were set up for the 4 prioritized domains: enthesitis, fatigue, structural damage, and physical function. Two instruments for measurement of physical function were provisionally endorsed: (1) the Health Assessment Questionnaire-Disability Index and (2) the physical functioning domain in the Medical Outcomes Study 36-item Short Form survey.Copyright © 2021 by The Journal of Rheumatology.

Published
2021

39. National scientific medical meeting 1995 abstracts: Oral presentations

Author

Norris, S., Collins, C., Hegarty, J., O’Farrelly, C., Carton, J., Madrigal, L., O’Donoghue, D. P., O’Farrelly, C., Holloway, H., Fielding, J. F., Mullins, W., Hone, S. W., Donnelly, M., Powell, F., Blayney, A. W., Cahill, E. A., Daly, S. F., Turner, M. J., Sullivan, P. A., McLoughlin, M., Skelly, M. M., Mulcahy, H. E., Connell, T., O’Donoghue, D. P., Duggan, C., Duffy, M. J., Troy, A., Sheahan, K., Whelan, A., Herra, C. M., Keane, C. T., Johnson, H., Lee, B., Doherty, E., McDonnell, T., Mulherin, D., FitzGerald, O., Bresnihan, B., Hassett, H. M., Boyce, A., Greig, V., O’Herlihy, C., Smyth, P. P. A., Roche, E. F., McCormack, I., Tempany, E., Cullen, M. J., Smith, D. F., Smyth, P. P. A., McBrinn, Y., Murray, B., Freaney, R., Keating, D., McKenna, M. J., O’Hare, J. A., Alam, H., Raza, Q., Geoghegan, M., Killalea, S., Hall, M., Feely, J., Kyne, L., O’Hara, B., Cullen, M., Rea, I. M., Donnelly, J. P., Stout, R. W., Lacey, P., Donnelly, M. J., McGrath, J., Hennessy, T. P., Timon, C. V. I., Hyde, D., Xia, H. X., Keane, C. T., Buckley, M., O’Morain, C., Buckley, M., Keating, S., Xia, H., Hyde, D., O’Morain, C., McGrath, J. P., Stuart, R. C., Lawlor, P., Byrne, P. J., Walsh, T. N., Hennessy, T. P. J., Skelly, M. M., Mulcahy, H. E., Connell, T., O’Donoghue, D. P., Duggan, C., Duffy, M., Troy, A., Sheahan, K., Norris, S., Tubridy, M., Redmond, J., Hegarty, J., Holloway, H., Fielding, J. F., Mullins, W., Monahan, K., Murphy, R. P., Headon, D. R., O’Gorman, T., O’Reilly, F. M., Darby, C., Fielding, J. F., Murphy, G. M., Murphy, A., Codd, M., Powell, F., Dervan, P., Lawlor, D., Loughlin, S. O., Flanagan, N., Watson, R., Barnes, L., Flanagan, N., Watson, R., Kilgallen, C., Sweeney, E., Mynes, A., Mooney, D., Donoghue, I., Browne, O., Kirrane, J. A., Murphy, G. M., McKenna, D., Young, M., McKenna, D., Young, M., O’Toole, E., Young, M., O’Briain, S., Srinivasan, U., Feighery, C., Leonard, N., Jones, E., O’Farrelly, C., Moloney, M. A., O’Farrelly, C., Weir, D. G., Lawler, M., O’Neill, A., Gowing, H., Pamphilon, D., McCann, S. R., O’Toole, G., Orren, A., Seifer, C. M., Crowley, D. C., Sheehan, G. J., Deignan, T., Kelly, J., O’Farrelly, C., Tormey, V. J., Faul, J., Leonard, C., Burke, C. M., Poulter, L. W., Collins, C., Lynch, S., Madrigal, L., Norris, S., McEntee, G., Traynor, O., Hegarty, J., O’Farrelly, C., Barry, E., Collins, C., Costello, P., Keavney, A., O’Donoghue, D. P., O’Farrelly, C., Willoughby, R., Feighery, C., O’Donnell, C., Cahill, M., Earley, A., Eustace, P., Osborne, R., Cahill, M., Saidlear, C., Holmes, B., Early, A., Eustace, P., Moran, A. P., Neisser, A., Polt, R. J., Bernheimer, H., Kainz, M., Schwerer, B., Gallagher, L., Cahill, M., Saidlear, C., Early, A., Firth, R., Eustace, P., Kennedy, N., McGilloway, E., Redmond, J., McGilloway, E., Kennedy, N., Tubridy, N., Shields, K., Cullen, W. K., Rowan, M. J., Moore, A. R., Rowan, M., Feely, J., Coakley, D., Lawlor, B., Swanwick, G., Al-Naeemi, R., Redmond, J., Murphy, R., Feely, J., Codd, N. M., Goggins, M., Kennedy, N. P., Mallon, B. L., Kennedy, N. P., Mulherin, D., FitzGerald, O., Bresnihan, B., Mulcahy, H., Skelly, M., Donoghue, D. O., McCarthy, D., Saunders, A., Mulherin, D., Bresnihan, B., FitzGerald, O., Veale, D. J., Belch, J. J. F., Mulherin, D., Bresnihan, B., FitzGerald, O., Veale, D. J., Belch, J. J. F., Mulherin, D., FitzGerald, O., Bresnihan, B., Costello, P., Breathnach, D., Murphy, E., Mulherin, D., FitzGerald, O., Bresnihan, B., Breathnach, D., Costello, P., Mulherin, D., Bresnihan, B., FitzGerald, O., Breathnach, D., Mulherin, D., Costello, P., Bresnihan, B., FitzGerald, O., Kernohan, G., Gibson, K., Wilson, A. G., Duff, G. W., de Vries, N., van de Putte, L. B. A., Donoghue, J., O’Kelly, F., Johnson, Z., Maher, T., Kyne, L., Moran, A., Keane, C., O’Neill, D., Horgan, N., Barragry, J. M., O’Neill, D., O’Herlihy, C., Campbell, D. M., Behan, M., O’Connell, P. R., Donnelly, V. S., Crowley, D., Geary, M., Boylan, P., Geary, M., Fanagan, M., Boylan, P., Hickey, K., Teoh, T., Doyle, M., Harrison, R., Hickey, K., Lyons, D., Shenouda, Y., Coughlan, M., McKenna, P., Hickey, K., Shenouda, Y., Lyons, D., McKenna, P., Coughlan, M., Lenehan, P., Foley, M., Kelehan, P., Ravichandran, P., Kelly, M., Conroy, A., Fitzpatrick, C., Egan, D., Regan, C. L., McAdam, B. V., McParland, P., Boylan, P., FitzGerald, G. A., Fitzgerald, D. J., Sharma, S. C., Foran, K., Barry-Kinsella, C., Harrison, R. F., Gillespie, F. J., O’Mahony, P., Boyle, M., White, M. J., Donohoe, F., Birrane, Y., Naughton, M., Tempany, E., Fitzsimons, R. B., Piracha, M., McConkey, S., Griffin, E., Hayes, E., Clarke, T., Parfrey, N., Butler, K., Fitzpatrick, C., Malone, A. J., Kearney, P. J., Duggan, P. F., Lane, A., Keville, R., Turner, M., Barry, S., Sloan, D., Gallagher, S., Darby, M., Galligan, P., Stack, J., Walsh, N., O’Sullivan, M., Fitzgerald, M., O’Sullivan, M., Meagher, D., Sloan, D., Browne, S., Meagher, D., Larkin, C., Lane, A., Casey, P., O’Callaghan, E., Walsh, N., Rooney, S., Walsh, E., Morris, M., Lane, A., Burke, T., Larkin, C., O’Callaghan, E., Browne, S., Roe, M., Lane, A., Larkin, C., O’Callaghan, E., Maher, C., Wrigley, M., Gill, M., Burgess, M., Corcoran, E., Walsh, D., Gilmer, B., Johnson, H., Hayes, C. B., Thornton, L., Fogarty, J., Lyons, R., O’Connor, M., Delaney, V., Buckley, K., Johnson, Z., Johnson, Z., Lillis, D., Delany, V., Hayes, C., Dack, P., Igoe, D., Gilmer, B., O’Neill, H. J., Johnson, H., Igoe, D., Delaney, V., Johnson, Z., Kelly, P., McKeown, D., Clancy, L., Varghese, G., Hennessy, S., Codd, M., Gilmartin, J. J., Birthistle, K., Carrington, D., Maguire, H., Atkinson, P., Foley-Nolan, C., Lynch, M., Cryan, B., Whyte, D., Cryan, B., Conlon, C., Foley-Nolan, C., Johnson, Z., Hayes, C., Delany, V., Kucinskas, V., Usinskiene, U., Sakalyte, I., Johnson, Z., Hayes, C., Delaney, V., Dack, P., Gill, M., Dawson, E., Molloy, K., Goulden, N., Lawler, M., McCann, S. R., Doyle, J., Lawlor, E., Lawler, M., Harrington, M. G., El-Nageh, N., Nolan, M. -L., El-Nageh, N., Nolan, M. -L., Harrington, M. G., Lawlor, E., O’Riordan, J., McCann, S. R., Judge, G., Crotty, G., Finch, T., Borton, M., Barnes, T., Gilligan, O., Lee, G., Limmer, R., Madden, M., Whyte, D., Cryan, B., Bergin, C., O’Leary, A., Keating, S., Mulcahy, F., Wallis, F., Glennon, M., Cormican, M., NiRiain, U., Heiginbothom, M., Gannon, F., Smith, T., O’Sullivan, C., Hone, R., Orren, A., Caugant, D. A., Fijen, C. A. P., Van Schalkwyk, E. J., Coetzee, G. J., Lynch, M., Cryan, B., Riain, U. Ni, Cormican, M. G., Park, L., Flynn, J., Glennon, M., O’Connor, M., Regazzoli, V., O’Connor, M., Hayes, M., Nicholson, G., Higgins, P., NiRiain, U., Flynn, N., Corbett-Feeney, G., Conway, D. J., Sheahan, K., O’Higgins, N. J., Smyth, P. P. A., Rajendiran, S., Byrne, J., Kilfeather, E., Dingle, P., Hunter, M., Kelehan, P., Al-Ghazal, S. K., Stanley, P., Palmer, J., Hong, A., Al-Ghazal, S. K., Saxby, P., Al-Ghazal, S. K., Saxby, P., McConkey, S., Sheehan, D., Regan, I., O’Mullane, J., Chaoimh, M. Ni, Leahy, M., Heffron, J. J., Lehane, M., Keohane, C., O’Leary, N., Sheehan, M., Renny-Walsh, E., Whelton, M. J., Doyle, C. T., Webster, J., Benjamin, N., Lyons, D., FitzGerald, S., Chadha, J. S., FitzGerald, M. G., FitzGerald, G. R., Hemeryck, L., McGettigan, P., Feely, J., McGettigan, P., Feely, J., McGettigan, P., Golden, J., Feely, J., Arthur, N., Wen, S. Y., Killalea, S., Deegan, P., McGettigan, P., Feely, J., Cooke, T., Adebayo, G. I., Feely, J., Gaffney, P., Sinnot, M., O’Riordan, D., Hayes, T., O’Connor, C. M., FitzGerald, M. X., Costello, C., Finlay, G., Hayes, J., O’Connor, C., FitzGerald, M. X., McMahon, K., O’Farrelly, C., O’Connor, C., FitzGerald, M. X., Donnelly, M. J., Hone, S., Robertson, J., Coakley, R., O’Neill, S., Walsh, M., McCarthy, J., Lannon, D., Wood, A. E., Sharkey, R., Mulloy, E., Long, M., Kilgallen, I., O’Neill, S., Faul, J., Tormey, V., Leonard, C., Burke, C. M., Poulter, L. W., Horne, S., Tormey, V. J., Faul, J., Leonard, C., Burke, C. M., Feeney, T., Muiré, Ó. Ó, Gilmartin, J. J., Griffin, M. J., Hughes, D., Knaggs, A., Magee, D., Donnelly, M., McCrory, C., March, B., Hone, R., Phelan, D., White, M., Fabry, J., Lynch, M., Buggy, D., Cooney, C., Hughes, D., McCrory, C., Aziz, E., O’Herlihy, C., Kelly, J., O’Keefe, D., McShane, A. J., Boylan, J., Tobin, E., Smith, T., Motherway, C., Colreavy, F., Denish, N., Dwyer, R., Bergin, A., O’Brien, K., MacSullivan, R., Carson, K. D., Blunnie, W. P., Moriarty, D. C., Carson, K. D., Blunnie, W. P., Moriarty, D. C., Kinirons, B., Lyons, B., Cregg, N., Casey, W., Moore, K. P., Colbert, S. A., Ecoffey, C., O’Gorman, D., Fitzgerald, J., Phelan, D., Diamond, P., Codd, M. B., Sugrue, D. D., Kellett, J., Tighe, M., McKenna, C. J., Galvin, J., McCann, H. A., Sugrue, D. D., McKenna, C. J., Codd, M. B., McCann, H. A., Sugrue, D. D., Scallon, A., Buckley, M., Fraser, A., Norton, M., Tomkin, G., Graham, I., Byrne, A., Maher, M., Moran, N., Fitzgerald, D., O’Callaghan, D., Coyle, D., Nugent, A. G., McGurk, C., Johnston, G. D., McGurk, C., Nugent, A., Silke, B., Nugent, A. G., Johnston, G. D., Murphy, N., Jennings, L., Pratico, D., Doyle, C., Fitzgerald, D., Hennessy, T., McCann, H., Sugrue, D., Hennessy, T., Codd, M., Donnelly, S., Hennessy, A., Hartigan, C., McCann, H., Sugrue, D., Hennessy, T., Codd, M., Donnelly, S., Hennessy, A., Hartigan, C., McCann, H., Sugrue, D., Hennessy, T., MacDonald, D., Blake, S., McCann, H., Sugrue, D., Hennessy, T., Sugrue, D., McCann, H., Hennessy, T., McCann, H., Sugrue, D., Hennessy, T., McDonald, D., Blake, S., Dominque, D., Sugrue, D., McMechan, S. R., MacKenzie, G., Allen, J., Wright, G. T., Dempsey, G. J., Crawley, M., Anderson, J., Adgey, A. A. J., Harbinson, M. T., Campbell, N. P. S., Wilson, C. M., Ellis, P. K., McIlrath, E. M., Freaney, R., McShane, A., Keaveny, T. V., McKenna, M. J., Rabenstein, K., Scheller, F., Pfeiffer, D., Urban, C., Moser, I., Jobst, G., Manz, A., Verpoorte, S., Dempsey, F., Diamond, D., Smyth, M., Rabenstein, K., Dempsey, E., McShane, A., Keaveny, T. V., McKenna, M. J., Freaney, R., Hamilton, V., Dwyer, R., Twomey, J., Crowley, R., Fenelon, L., Walsh, F., McCann, J., McDonagh, P., White, M., McGovern, E., Luke, D., Phelan, D., McCrory, C., Crowley, K., Lyons, B., Mannion, D., Wood, A. E., Casey, W., Murphy, D., Clarkson, K., Carton, E., Higgins, P., Leonard, I., O’Toole, D., Staunton, M., Phelan, D., Srinivasan, U., Leonard, N., Jones, E., Moloney, M. A., Weir, D. G., O’Farrelly, C., Feighery, C., Griffin, M., Owens, D., Collins, P., Johnson, A., Tomkin, G. H., Herity, N. A., Allen, J. D., Silke, B., Adgey, A. A. J., O’Reilly, F. M., Darby, C., O’Moore, R., Fielding, J. F., Murphy, G. M., Crotty, G. M., Judge, G., McCann, S. R., DeArce, M., Nugent, A. G., McGurk, C., Johnston, G. D., Nikookam, K., Keenan, P., Cregan, D., Firth, R., O’Meara, N., Forman, S., Cusack, D. A., and Farrell, B.

Published
1995
Full Text
View/download PDF

40. Irish society for rheumatology: Proceedings of annual general meeting held in Beaumont Hospital on Friday 22nd October, 1993

Author

Mulherin, Diarmuid, FitzGerald, Oliver, Bresnihan, Barry, Bruce, I. N., McNally, J. A., Bell, A. L., Yanni, G., Cauli, A., Challacombe, S., Panayi, G. S., Foley-Nolan, D., Akil, M., Anthony, M., Cundall, D., Bourne, J., Arthur, R., Chamberlain, M. A., Byrne, P., Mahon, N., Robinson, H., Sant, S. M., Donnelly, S., Barnes, L., Watson, R., Casey, E. B., Donnelly, S., Casey, E. B., Bruce, I. N., Edgar, D. E., McMillan, S. A., Conlan, S. K., McNeill, T. A., Bell, A. L., Robinson, H., Byrne, P., Mahon, N., Sant, S. M., Abuzakouk, M., Feighery, C., Jones, E., O’Briain, S., Goggins, M., Weir, D. G., Casey, E., O’Farrelly, C., Kelleher, D., Murphy, A., Casey, E. B., Veale, D. J., Kirk, G., McLaren, M., Belch, J. J. F., Byrne, P., Mahon, N., Robinson, H., Sant, S. M., Foley-Nolan, D., Daly, M. J., Mahon, N., Robinson, H., Byrne, P., Sant, S. M., Donnelly, S., Murphy, J., Lynch, M., Casey, E. B., McKernan, S., Donnelly, S., Casey, E. B., Sothinathan, R., Donnelly, S., Casey, E. B., Blake, C., Garrett, M., Robinson, H., Byrne, P., Mahon, N., Sant, S. M., Gourley, I. S., Bell, A. L., Bresnihan, B., FitzGerald, O., Cunnane, G., Abuzakouk, M., Feighery, C., Bergin, C., Cherukuri, A., Weir, D. G., Casey, E., O’Farrelly, C., Mulherin, D., Kirk, G., Veale, D. J., Belch, J. J. F., Bresnihan, B., FitzGerald, O., Kelleher, D., Hall, N., Murphy, A., Casey, E. B., Mulcahy, B., Molloy, M., Phelan, M., O’Gara, F., McConnell, F., Shanahan, F., FitzGerald, O., Heffernan, M., Mulcahy, B., Neary, P., and Molloy, M.

Published
1994
Full Text
View/download PDF

41. Blood pressure postpartum (BP2) RCT protocol: Follow-up and lifestyle behaviour change strategies in the first 12 months after hypertensive pregnancy

Author

Henry A, Arnott C, Makris A, Davis G, Hennessy A, Beech A, Pettit F, Se Homer C, Craig ME, Roberts L, Hyett J, Chambers G, Fitzgerald O, Gow M, Mann L, Challis D, Gale M, Ruhotas A, Kirwin E, Denney-Wilson E, and Brown M

Subjects
1114 Paediatrics and Reproductive Medicine
Abstract

OBJECTIVES:Women who had hypertensive disorders of pregnancy (HDP) are twice as likely to experience maternal cardiovascular disease later in life. The primary aim of this study (BP2) is to compare outcomes of 3 different management strategies, including lifestyle behaviour change (LBC), in the first 12 months postpartum in women who had HDP in their preceding pregnancy. Secondary aims include assessing the effects on other cardiometabolic parameters. STUDY DESIGN:Three-arm multicentre randomised trial in metropolitan Australian hospitals, (registration: ACTRN12618002004246) target sample size 480. Participants are randomised to one of three groups: 1) Optimised usual care: information package and family doctor follow-up 6 months postpartum 2) Brief intervention: information package as per group 1, plus assessment and brief LBC counselling at a specialised clinic with an obstetric physician and dietitian 6 months postpartum 3) Extended intervention: as per group 2 plus enrolment into a 6 month telephone-based LBC program from 6 to 12 months postpartum. All women have an outcome assessment at 12 months. MAIN OUTCOME MEASURES:Primary outcomes: (a) BP change or (b) weight change and/or waist circumference change. SECONDARY OUTCOMES:maternal health-related quality of life, engagement and retention in LBC program, biochemical markers, vascular function testing, infant weight trajectory, incremental cost-effectiveness ratios. The study is powered to detect a 4 mmHg difference in systolic BP between groups, or a 4 kg weight loss difference/2cm waist circumference change. CONCLUSIONS:BP2 will provide evidence regarding the feasibility and effectiveness of postpartum LBC interventions and structured clinical follow-up in improving cardiovascular health markers after HDP.

Published
2020

42. Blood pressure postpartum (BP2) RCT protocol: Follow-up and lifestyle behaviour change strategies in the first 12 months after hypertensive pregnancy

Author

Henry, A, Arnott, C, Makris, A, Davis, G, Hennessy, A, Beech, A, Pettit, F, SE Homer, C, Craig, ME, Roberts, L, Hyett, J, Chambers, G, Fitzgerald, O, Gow, M, Mann, L, Challis, D, Gale, M, Ruhotas, A, Kirwin, E, Denney-Wilson, E, Brown, M, Henry, A, Arnott, C, Makris, A, Davis, G, Hennessy, A, Beech, A, Pettit, F, SE Homer, C, Craig, ME, Roberts, L, Hyett, J, Chambers, G, Fitzgerald, O, Gow, M, Mann, L, Challis, D, Gale, M, Ruhotas, A, Kirwin, E, Denney-Wilson, E, and Brown, M

Abstract

Objectives: Women who had hypertensive disorders of pregnancy (HDP) are twice as likely to experience maternal cardiovascular disease later in life. The primary aim of this study (BP2) is to compare outcomes of 3 different management strategies, including lifestyle behaviour change (LBC), in the first 12 months postpartum in women who had HDP in their preceding pregnancy. Secondary aims include assessing the effects on other cardiometabolic parameters. Study design: Three-arm multicentre randomised trial in metropolitan Australian hospitals, (registration: ACTRN12618002004246) target sample size 480. Participants are randomised to one of three groups: 1) Optimised usual care: information package and family doctor follow-up 6 months postpartum 2) Brief intervention: information package as per group 1, plus assessment and brief LBC counselling at a specialised clinic with an obstetric physician and dietitian 6 months postpartum 3) Extended intervention: as per group 2 plus enrolment into a 6 month telephone-based LBC program from 6 to 12 months postpartum. All women have an outcome assessment at 12 months. Main outcome measures: Primary outcomes: (a) BP change or (b) weight change and/or waist circumference change. Secondary outcomes: maternal health-related quality of life, engagement and retention in LBC program, biochemical markers, vascular function testing, infant weight trajectory, incremental cost-effectiveness ratios. The study is powered to detect a 4 mmHg difference in systolic BP between groups, or a 4 kg weight loss difference/2cm waist circumference change. Conclusions: BP2 will provide evidence regarding the feasibility and effectiveness of postpartum LBC interventions and structured clinical follow-up in improving cardiovascular health markers after HDP.

Published
2020

43. The grappa-omeract working group: 4 prioritized domains for completing the core outcome measurement set for psoriatic arthritis 2019 updates.

Author

Mease P.J., Antony A., Gladman D.D., Goel N., Strand V., Duffin K.C., Lindsay C.A., De Wit M., FitzGerald O., Leung Y.Y., Tillett W., Orbai A.-M., Ogdie A., Eder L., Coates L.C., Holland R., Mease P.J., Antony A., Gladman D.D., Goel N., Strand V., Duffin K.C., Lindsay C.A., De Wit M., FitzGerald O., Leung Y.Y., Tillett W., Orbai A.-M., Ogdie A., Eder L., Coates L.C., and Holland R.

Abstract

The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Outcome Measures in Rheumatology (OMERACT) Psoriatic Arthritis (PsA) working group provided updates at the 2019 GRAPPA annual meeting on its work toward developing a core outcome set for PsA. The working group prioritized 4 domains, including musculoskeletal disease activity (enthesitis and dactylitis), fatigue, physical function, and structural damage. In this report, the working group summarizes its progress in standardizing the core outcome set for these 4 domains.Copyright © 2020 Journal of Rheumatology. All rights reserved.

Published
2020

44. Reliability of composite measures for the assessment of psoriatic arthritis.

Author

Packham J., Antony A., Coates L.C., Jadon D., Creamer P., Lane S., Massarotti M., Cavill C., Brooke M., Korendowych E., Mchugh N., Lissina A., Tillett W., Helliwell P., Fitzgerald O., Waxman R., Packham J., Antony A., Coates L.C., Jadon D., Creamer P., Lane S., Massarotti M., Cavill C., Brooke M., Korendowych E., Mchugh N., Lissina A., Tillett W., Helliwell P., Fitzgerald O., and Waxman R.

Abstract

Background: Composite measures of disease activity have been developed for use in Psoriatic Arthritis (PsA) to capture the wide spectrum of disease but there is a lack of consensus regarding which to adopt for routine practice. It is recognised that more data is required to understand the measurement properties of existing instruments and consider the impact of modifications that may improve face validity, responsiveness or feasibility. It is important to have an estimate of a measurement instrument's reliability in the setting of stable disease in order to understand measurement error and responsiveness. To our knowledge no data exists on the stability of composite measures in PsA. Objective(s): To measure test re-test reliability of composite measures of disease activity in PsA. Method(s): Clinical and patient reported outcomes to enable the calculation of composite measures were administered to 141 patients with PsA at five time points in a UK multicentre observational study. All patients fulfilled the CASPAR criteria. Twenty-nine patients with clinically stable disease and receiving no treatment intervention underwent repeat assessment by the same examiner within 2 weeks. Patients in high and low disease were included. Reliability was evaluated by intra-class correlation coefficient (ICC) and Bland Altman plots. Result(s): Of the 29 patients included 15 were male, the mean age was 52.4 years (SD 13.39), mean disease duration at T0 was 9.2yrs (SD 8.11). The mean swollen joint count was 3.4 (SD 5.1), tender joint count 11.3 (SD 15.03) and PASI 1.0 (SD1.04). The ICC (95% CI) for tender and swollen joint counts were 0.94 (0.87-0.97) and 0.91 (0.80-0.96) respectively. The ICC for PASI was 0.95 (0.90-0.98). All composite measures demonstrated high levels of test-retest reliability with ICC >0.85, table. The most reliable measure was the PADAS ICC 0.98 (95% CI 0.954-0.991). The individual ICC for each composite measures are reported in the table and Bland Altman plots

Published
2020

46. Irish association of rheumatology&rehabilitation: Proceedings of Annual General Meeting held November 1991

Author

O’Byrne, J., Eustace, S., Stephens, M. M., Farahat, M. N. M. R., Yanni, G., Posten, R., Panayi, G. S., Sant, S., Costello, R., Barry, M., Hassan, J., Feighery, C., Bresnihan, B., Whelan, A., Coakley, F., Paor, A. M. de, Reilly, R. B., Casey, E. B., Tormey, V. J., Kearns, G., Gaffney, K., Freyne, P. J., Callaghan, M., FitzGerald, O., Veale, D., O’Nuallain, E., Reen, D., Veale, D., Farrell, M., FitzGerald, O., Rogers, S., Barnes, L., Coughlan, R. J., McCarthy, C., McDermott, M., Hourihane, D., O'Morain, C., O'Reilly, S., Hartley, P., Casey, E., Clancy, L., Mulcahy, F., Hall, N., Murphy, A., Breen, C., Kelleher, D., Abuzakouk, M., and O'Farrelly, C.

Published
1992
Full Text
View/download PDF

47. Irish association of Rheumatology & Rehabilitation: Proceedings of the annual general meeting, friday, 16th november, 1990

Author

Etwebi, A. B., Comerford, F. R., Callaghan, Maire, Mulherin, D., Whelan, A., Feighery, C., FitzGerald, M. X., Bresnihan, B., Bell, A. L., Markey, G. M., Alexander, H. D., Morris, M., McNally, J. A., O’Byrne, S., Hall, M., Cuffe, J. T., Feely, J., Casey, E. B., de Paor, A., Reilly, R., Casey, Eoin, McCormack, B., Kearns, G., Beirne, C., Ryan, D., Kearns, G. D., Casey, E. B., Nuallain, E. M., Reen, D. J., Kelleher, D., Murphy, Anne, Feighery, C., Casey, E. B., Cullen, D., Kelleher, D., Murphy, A., Keams, G., Feighery, C., Casey, E. B., Foley-Nolan, D., Brady, A., Stack, J., Barry, C., Ennis, J., Coughlan, R. J., Foley-Nolan, D., Murray, P., Campbell, E., Keogh, B., Coughlan, R. J., O’Donoghue, J., Foley-Nolan, D., Woods, R., Choudhry, L., Byrne, P., Barry, C., Coughlan, R. J., McCarthy, C. J., Regan, Marian, Coughlan, R. J., Barry, C., McCarthy, J., Coughlin, R. J., Barry, C., McCarthy, C., Foley-Nolan, D., Coughlan, R., Barry, C., Sant, T. J., Healy, S., Casey, E. B., Healy, E., Sant, S., Tyrrell, J., Casey, E. B., Sant, S., Barry, M., Murphy, G., Sant, S., Barry, M., Murphy, G., Veale, D., Rogers, S., Barnes, L., FitzGerald, O., Cooney, J., Veale, D., McQuillan, R., Leahy, A., Barton, J., McMahon, M., Bouchier-Hayes, C., Courtney, G., Doyle, J. S., FitzGerald, O., Taggart, A. J., McEvoy, F., Heylings, D., McMillin, P., Hassan, J., Yarani, G., Feighery, C., Bresnihan, B., Whelan, A., Doherty, Eva, Bresnihan, B., Harden, Catherine, Feighery, C., Jackson, J., Yanni, G., Whelan, A., Feighery, C., Bresnihan, B., Yanni, G., Whelan, A., Feighery, C., FitzGerald, O., Breshihan, B., Shaw, B., and FitzGerald, O.

Published
1991
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results